Table 2 Univariate and multivariate cox hazards analysis of the primary cohort
Characteristic | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Age, n (%) | ||||
< 59 vs. ≥ 59 | 0.854 (0.478–1.528) | 0.596 | ||
Sex, n (%) | ||||
Male vs. Female | 1.043 (0.515–2.113) | 0.906 | ||
BMI, n (%) | ||||
< 18.5 vs. 18.5–24 vs. ≥ 24 | 1.085 (0.646–1.821) | 0.758 | ||
Alcohol, n (%) | ||||
No/Yes | 0.946 (0.441–2.031) | 0.887 | ||
Smoking, n (%) | ||||
No/Yes | 1.360 (0.758–2.442) | 0.303 | ||
Histology, n (%) | ||||
Adenocarcinoma / Squamous cell carcinoma | 1.646 (0.914–2.963) | 0.097 | ||
No. of metastatic sites, n (%) | ||||
< 2 vs. ≥ 2 | 1.038 (0.563–1.913) | 0.904 | ||
Pleural metastasis, n (%) | ||||
Absent vs. Present | 2.172 (1.214–3.883) | 0.009 | 2.980 (1.521–5.837) | 0.001 |
Lung metastasis, n (%) | ||||
Absent vs. Present | 0.688 (0.365–1.298) | 0.248 | ||
Brain metastasis, n (%) | ||||
Absent vs. Present | 0.784 (0.309–1.989) | 0.609 | ||
Liver metastasis, n (%) | ||||
Absent vs. Present | 1.296 (0.603–2.782) | 0.506 | ||
Bone metastasis, n (%) | ||||
Absent vs. Present | 1.002 (0.509–1.973) | 0.995 | ||
WBC, 109/L | ||||
< 11.80 vs. ≥ 11.80 | 4.185 (1.989–8.809) | < 0.001 | ||
Neutrophils, 109/L | ||||
< 10.00 vs. ≥ 10.00 | 6.590 (3.130–13.877) | < 0.001 | 5.139 (2.081–12.691) | < 0.001 |
Lymphocytes, 109/L | ||||
< 1.71 vs. ≥ 1.71 | 0.293 (0.141–0.609) | 0.001 | 0.331 (0.142–0.771) | 0.010 |
Monocytes, 109/L | ||||
< 0.43 vs. ≥ 0.43 | 0.941 (0.513–1.728) | 0.846 | ||
NLR | ||||
< 4.90 vs. ≥ 4.90 | 3.439 (1.854–6.381) | < 0.001 | ||
LMR | ||||
< 2.76 vs. ≥ 2.76 | 0.367 (0.200–0.673) | < 0.001 | ||
PLR | ||||
< 81.98 vs. ≥ 81.98 | 0.697 (0.215–2.263) | 0.548 | ||
PLT, 109/L | ||||
< 273.00 vs. ≥ 273.00 | 0.612 (0.317–1.185) | 0.145 | ||
PT, s | ||||
< 11.30 vs. ≥ 11.30 | 1.726 (0.819–3.637) | 0.152 | ||
APTT, s | ||||
< 27.50 vs. ≥ 27.50 | 1.738 (0.923–3.273) | 0.087 | ||
Fbg, g/L | ||||
< 4.82 vs. ≥ 4.82 | 0.892 (0.450–1.769) | 0.743 | ||
TT, s | ||||
< 17.60 vs. ≥ 17.60 | 1.121 (0.583–2.158) | 0.732 | ||
CD3 + cells, % | ||||
< 67.20 vs. ≥ 67.20 | 0.694 (0.371–1.298) | 0.252 | ||
CD3 + CD4 + cells, % | ||||
< 40.40 vs. ≥ 40.40 | 0.451 (0.207–0.984) | 0.045 | ||
CD3 + CD8 + cells, % | ||||
< 16.70 vs. ≥ 16.70 | 2.809 (0.675–11.697) | 0.156 | ||
B cells, % | ||||
< 4.23 vs. ≥ 4.23 | 0.275 (0.133–0.568) | < 0.001 | 0.329 (0.151–0.714) | 0.005 |
CD3-CD16 + CD56 + cells, % | ||||
< 16.10 vs. ≥ 16.10 | 2.229 (1.056–4.705) | 0.035 | ||
Treg cells, % | ||||
< 35.80 vs. ≥ 35.80 | 3.197 (1.628–6.280) | 0.001 | 2.934 (1.478–5.826) | 0.002 |
CD8 + CD25 + cells, % | ||||
< 5.95 vs. ≥ 5.95 | 0.539 (0.284–1.024) | 0.059 | ||
TNM stage | ||||
Stage II vs stage III vs stage IV | 1.574 (0.782–3.167) | 0.204 | ||